Do analysts rate QUCY or BMRA?

Biomerica has a consensus target price of $9.00, suggesting a potential upside of 423.26%. Given Biomerica's higher probable upside, analysts plainly believe Biomerica is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Biomerica 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, QUCY or BMRA?

Biomerica has higher revenue and earnings than Mainz Biomed. Biomerica is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $537.08K 42.99 -$16.21M -$47.60 N/A Biomerica $5.31M 1.00 -$4.97M -$0.89 N/A

Does the media prefer QUCY or BMRA?

In the previous week, Mainz Biomed had 1 more articles in the media than Biomerica. MarketBeat recorded 4 mentions for Mainz Biomed and 3 mentions for Biomerica. Biomerica's average media sentiment score of 0.96 beat Mainz Biomed's score of 0.48 indicating that Biomerica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomerica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RKTO or BMRA?

In the previous week, Biomerica had 1 more articles in the media than Rocket One Inc. Common Stock. MarketBeat recorded 3 mentions for Biomerica and 2 mentions for Rocket One Inc. Common Stock. Biomerica's average media sentiment score of 0.96 beat Rocket One Inc. Common Stock's score of 0.94 indicating that Biomerica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket One Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biomerica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BMRA or ALVR?

Biomerica presently has a consensus target price of $9.00, indicating a potential upside of 423.26%. Given Biomerica's stronger consensus rating and higher probable upside, equities research analysts plainly believe Biomerica is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BMRA or ALVR more profitable?

AlloVir has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. AlloVir's return on equity of -71.03% beat Biomerica's return on equity. Company Net Margins Return on Equity Return on Assets Biomerica -96.49% -98.14% -70.42% AlloVir N/A -71.03% -61.27%

Is CELU or BMRA more profitable?

Biomerica has a net margin of -96.49% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Biomerica's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% Biomerica -96.49% -98.14% -70.42%

Biomerica (BMRA) Competitors

$1.72 -0.05 (-2.82%)

As of 11:42 AM Eastern

Compare

BMRA vs. MRKR, QUCY, RKTO, ALVR, and CELU

Should you buy Biomerica stock or one of its competitors? MarketBeat compares Biomerica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biomerica include Marker Therapeutics (MRKR), Mainz Biomed (QUCY), Rocket One Inc. Common Stock (RKTO), AlloVir (ALVR), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry.

How does Biomerica compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Biomerica had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Biomerica and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.96 equaled Biomerica'saverage media sentiment score.

Company	Overall Sentiment
Marker Therapeutics	Positive
Biomerica	Positive

Marker Therapeutics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Biomerica has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by insiders. Comparatively, 18.0% of Biomerica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Biomerica has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.86	-$12.16M	-$0.61	N/A
Biomerica	$5.31M	1.00	-$4.97M	-$0.89	N/A

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 584.93%. Biomerica has a consensus target price of $9.00, suggesting a potential upside of 423.26%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biomerica has a net margin of -96.49% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Biomerica	-96.49%	-98.14%	-70.42%

Summary

Marker Therapeutics beats Biomerica on 9 of the 15 factors compared between the two stocks.

How does Biomerica compare to Mainz Biomed?

Mainz Biomed (NASDAQ:QUCY) and Biomerica (NASDAQ:BMRA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Biomerica has higher revenue and earnings than Mainz Biomed. Biomerica is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$537.08K	42.99	-$16.21M	-$47.60	N/A
Biomerica	$5.31M	1.00	-$4.97M	-$0.89	N/A

Mainz Biomed has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Mainz Biomed's return on equity of 0.00% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Biomerica	-96.49%	-98.14%	-70.42%

22.3% of Biomerica shares are owned by institutional investors. 3.1% of Mainz Biomed shares are owned by company insiders. Comparatively, 18.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Mainz Biomed has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, Biomerica has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

In the previous week, Mainz Biomed had 1 more articles in the media than Biomerica. MarketBeat recorded 4 mentions for Mainz Biomed and 3 mentions for Biomerica. Biomerica's average media sentiment score of 0.96 beat Mainz Biomed's score of 0.48 indicating that Biomerica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomerica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biomerica has a consensus target price of $9.00, suggesting a potential upside of 423.26%. Given Biomerica's higher probable upside, analysts plainly believe Biomerica is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Mainz Biomed beats Biomerica on 8 of the 15 factors compared between the two stocks.

How does Biomerica compare to Rocket One Inc. Common Stock?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Rocket One Inc. Common Stock has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Biomerica has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Rocket One Inc. Common Stock has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Biomerica's return on equity of -98.14% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Biomerica	-96.49%	-98.14%	-70.42%

In the previous week, Biomerica had 1 more articles in the media than Rocket One Inc. Common Stock. MarketBeat recorded 3 mentions for Biomerica and 2 mentions for Rocket One Inc. Common Stock. Biomerica's average media sentiment score of 0.96 beat Rocket One Inc. Common Stock's score of 0.94 indicating that Biomerica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket One Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomerica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are owned by company insiders. Comparatively, 18.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Biomerica has higher revenue and earnings than Rocket One Inc. Common Stock. Biomerica is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Biomerica	$5.31M	1.00	-$4.97M	-$0.89	N/A

Rocket One Inc. Common Stock presently has a consensus price target of $5.00, suggesting a potential upside of 430.34%. Biomerica has a consensus price target of $9.00, suggesting a potential upside of 423.26%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher possible upside, equities analysts plainly believe Rocket One Inc. Common Stock is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Biomerica beats Rocket One Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

How does Biomerica compare to AlloVir?

Biomerica (NASDAQ:BMRA) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

AlloVir has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. AlloVir's return on equity of -71.03% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
AlloVir	N/A	-71.03%	-61.27%

22.3% of Biomerica shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 18.0% of Biomerica shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Biomerica has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

Biomerica presently has a consensus target price of $9.00, indicating a potential upside of 423.26%. Given Biomerica's stronger consensus rating and higher probable upside, equities research analysts plainly believe Biomerica is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Biomerica has higher revenue and earnings than AlloVir. Biomerica is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$5.31M	1.00	-$4.97M	-$0.89	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

In the previous week, Biomerica had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Biomerica and 0 mentions for AlloVir. Biomerica's average media sentiment score of 0.96 beat AlloVir's score of 0.00 indicating that Biomerica is being referred to more favorably in the media.

Company	Overall Sentiment
Biomerica	Positive
AlloVir	Neutral

Summary

Biomerica and AlloVir tied by winning 7 of the 14 factors compared between the two stocks.

How does Biomerica compare to Celularity?

Celularity (NASDAQ:CELU) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Biomerica had 2 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Biomerica and 1 mentions for Celularity. Celularity's average media sentiment score of 1.89 beat Biomerica's score of 0.96 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Very Positive
Biomerica	Positive

Biomerica has a net margin of -96.49% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Biomerica	-96.49%	-98.14%	-70.42%

Biomerica has lower revenue, but higher earnings than Celularity. Biomerica is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.66	-$91.72M	-$3.33	N/A
Biomerica	$5.31M	1.00	-$4.97M	-$0.89	N/A

Celularity presently has a consensus target price of $6.00, indicating a potential upside of 888.47%. Biomerica has a consensus target price of $9.00, indicating a potential upside of 423.26%. Given Celularity's stronger consensus rating and higher probable upside, equities analysts clearly believe Celularity is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

19.0% of Celularity shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 17.3% of Celularity shares are held by insiders. Comparatively, 18.0% of Biomerica shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Celularity has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Biomerica has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Summary

Celularity and Biomerica tied by winning 8 of the 16 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMRA vs. The Competition

Export

Metric	Biomerica	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.32M	$3.04B	$6.76B	$12.51B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-1.93	19.59	25.78	24.73
Price / Sales	1.00	361.90	548.02	103.35
Price / Cash	N/A	56.85	29.14	36.96
Price / Book	1.07	4.27	10.84	6.52
Net Income	-$4.97M	$64.45M	$3.57B	$336.86M
7 Day Performance	-2.27%	3.08%	2.43%	1.31%
1 Month Performance	-28.48%	3.79%	0.76%	0.36%
1 Year Performance	-45.57%	34.58%	36.68%	30.89%

Biomerica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMRA Biomerica	2.4116 of 5 stars	$1.72 -2.8%	$9.00 +423.3%	-43.8%	$5.32M	$5.31M	N/A	60	Short Interest Decrease
MRKR Marker Therapeutics	2.244 of 5 stars	$1.37 flat	$10.00 +629.9%	+0.0%	$22.84M	$3.55M	N/A	60
QUCY Mainz Biomed	0.3083 of 5 stars	$1.49 -3.2%	N/A	N/A	$22.58M	$540K	N/A	30
RKTO Rocket One Inc. Common Stock	2.2146 of 5 stars	$1.03 +2.0%	$5.00 +385.4%	-14.9%	$22.55M	N/A	N/A	4
ALVR AlloVir	N/A	$4.40 -6.8%	N/A	+64.9%	$22.19M	N/A	N/A	110	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMRA) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomerica (BMRA) Competitors

BMRA vs. MRKR, QUCY, RKTO, ALVR, and CELU

How does Biomerica compare to Marker Therapeutics?

Summary

How does Biomerica compare to Mainz Biomed?

Summary

How does Biomerica compare to Rocket One Inc. Common Stock?

Summary

How does Biomerica compare to AlloVir?

Summary

How does Biomerica compare to Celularity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA vs. The Competition

Biomerica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biomerica (BMRA) Competitors

BMRA vs. MRKR, QUCY, RKTO, ALVR, and CELU

How does Biomerica compare to Marker Therapeutics?

Does the media refer more to MRKR or BMRA?

Which has more risk & volatility, MRKR or BMRA?

Do insiders and institutionals hold more shares of MRKR or BMRA?

Which has better earnings & valuation, MRKR or BMRA?

Do analysts recommend MRKR or BMRA?

Is MRKR or BMRA more profitable?

Summary

How does Biomerica compare to Mainz Biomed?

Which has preferable valuation & earnings, QUCY or BMRA?

Is QUCY or BMRA more profitable?

Do insiders and institutionals hold more shares of QUCY or BMRA?

Which has more risk and volatility, QUCY or BMRA?

Does the media prefer QUCY or BMRA?

Do analysts rate QUCY or BMRA?

Summary

How does Biomerica compare to Rocket One Inc. Common Stock?

Which has more volatility & risk, RKTO or BMRA?

Is RKTO or BMRA more profitable?

Does the media refer more to RKTO or BMRA?

Do insiders & institutionals have more ownership in RKTO or BMRA?

Which has stronger earnings & valuation, RKTO or BMRA?

Do analysts prefer RKTO or BMRA?

Summary

How does Biomerica compare to AlloVir?

Is BMRA or ALVR more profitable?

Do insiders & institutionals believe in BMRA or ALVR?

Which has more volatility and risk, BMRA or ALVR?

Do analysts recommend BMRA or ALVR?

Which has preferable valuation and earnings, BMRA or ALVR?

Does the media favor BMRA or ALVR?

Summary

How does Biomerica compare to Celularity?

Does the media refer more to CELU or BMRA?

Is CELU or BMRA more profitable?

Which has stronger earnings & valuation, CELU or BMRA?

Do analysts prefer CELU or BMRA?

Do insiders and institutionals believe in CELU or BMRA?

Which has more risk & volatility, CELU or BMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA vs. The Competition

Biomerica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools